Filing Details

Accession Number:
0001764013-24-000135
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-07-19 17:39:46
Reporting Period:
2024-07-17
Accepted Time:
2024-07-19 17:39:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1764013 Immunovant Inc. IMVT Biological Products, (No Disgnostic Substances) (2836) 832771572
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1883766 Renee Eva Barnett C/O Immunovant, Inc.
320 W 37Th Street, 6Th Floor
New York NY 10018
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-07-17 2,939 $29.64 347,728 No 4 S Direct
Common Stock Disposition 2024-07-17 184 $30.55 347,544 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on July 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 - $30.28 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 - $30.84 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.